DOP2016000076A - Tienouracilcarboxamidas cíclicas y usos de las mismas - Google Patents

Tienouracilcarboxamidas cíclicas y usos de las mismas

Info

Publication number
DOP2016000076A
DOP2016000076A DO2016000076A DO2016000076A DOP2016000076A DO P2016000076 A DOP2016000076 A DO P2016000076A DO 2016000076 A DO2016000076 A DO 2016000076A DO 2016000076 A DO2016000076 A DO 2016000076A DO P2016000076 A DOP2016000076 A DO P2016000076A
Authority
DO
Dominican Republic
Prior art keywords
prevention
treatment
tienouracilcarboxamidas
same
diseases
Prior art date
Application number
DO2016000076A
Other languages
English (en)
Inventor
Klemens Lustig
Raimund Kast
Martina Delbeck
Michael Harter
Berndt Kalthof
Niels Lindner
Pierre Wasnaire
Frank Süssmeier
Original Assignee
Bayer Pharma Aktiengesellscharft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellscharft filed Critical Bayer Pharma Aktiengesellscharft
Publication of DOP2016000076A publication Critical patent/DOP2016000076A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA PRESENTE SOLICITUD SE RELACIONA CON NOVEDOSOS DERIVADOS DE 2,4-DIOXO-1,2,3,4-TETRAHIDROTIENO[2,3-D]PIRIMIDINA-6-CARBOXAMIDA ("TIENOURACIL"-CARBOXAMIDAS), CON PROCESOS PARA SU PREPARACIÓN, CON SU USO SOLO O EN COMBINACIONES PARA EL TRATAMIENTO Y/O PREVENCIÓN DE ENFERMEDADES Y CON SU USO PARA LA PREPARACIÓN DE MEDICAMENTOS PARA EL TRATAMIENTO Y/O PREVENCIÓN DE ENFERMEDADES, EN PARTICULAR PARA EL TRATAMIENTO Y/O PREVENCIÓN DE TRASTORNOS PULMONARES Y CARDIOVASCULARES.
DO2016000076A 2013-10-07 2016-04-05 Tienouracilcarboxamidas cíclicas y usos de las mismas DOP2016000076A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13187487 2013-10-07
EP14152518 2014-01-24

Publications (1)

Publication Number Publication Date
DOP2016000076A true DOP2016000076A (es) 2016-05-15

Family

ID=51655757

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2016000076A DOP2016000076A (es) 2013-10-07 2016-04-05 Tienouracilcarboxamidas cíclicas y usos de las mismas

Country Status (24)

Country Link
US (2) US9604996B2 (es)
EP (1) EP3055313B1 (es)
JP (1) JP2016532721A (es)
KR (1) KR20160065957A (es)
CN (1) CN105793267B (es)
AP (1) AP2016009128A0 (es)
AU (1) AU2014334040A1 (es)
BR (1) BR112016007238A2 (es)
CA (1) CA2926223A1 (es)
CR (1) CR20160155A (es)
CU (1) CU20160044A7 (es)
DO (1) DOP2016000076A (es)
EA (1) EA201600318A1 (es)
ES (1) ES2659043T3 (es)
IL (1) IL244751A0 (es)
MX (1) MX2016004250A (es)
NI (1) NI201600047A (es)
PE (1) PE20160562A1 (es)
PH (1) PH12016500608A1 (es)
SG (1) SG11201602397XA (es)
TN (1) TN2016000121A1 (es)
TW (1) TW201607950A (es)
UY (1) UY35771A (es)
WO (1) WO2015052065A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170081178A (ko) * 2014-11-03 2017-07-11 바이엘 파마 악티엔게젤샤프트 히드록시알킬-치환된 페닐트리아졸 유도체 및 그의 용도
UY36586A (es) * 2015-03-26 2016-10-31 Bayer Pharma AG Heterociclilmetiltienouracilos y uso de los mismos
KR20190049691A (ko) * 2016-07-07 2019-05-09 카듀리온 파마슈티칼스, 엘엘씨 심부전의 치료 방법
WO2018041771A1 (de) 2016-09-02 2018-03-08 Bayer Pharma Aktiengesellschaft (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung
EP3515919A1 (de) 2016-09-23 2019-07-31 Bayer Aktiengesellschaft N3-cyclisch substituierte thienouracile und ihre verwendung
WO2021252951A1 (en) 2020-06-12 2021-12-16 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
MA71568A (fr) * 2022-08-16 2025-05-30 Cms Research & Development Pte. Ltd. Forme saline et forme cristalline de dérivé de thiénopyrimidinone

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5344830A (en) 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
SE9702001D0 (sv) 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
CA2339664A1 (en) 1998-08-28 2000-03-09 Astrazeneca Ab Thieno{2,3,-d}pyrimidinedione derivatives and their use as immunosuppressants
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
PA8539301A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
WO2002064598A1 (en) * 2001-02-14 2002-08-22 Warner-Lambert Company Llc Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
US6951849B2 (en) 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
EP1467995B1 (en) * 2001-12-20 2010-05-19 OSI Pharmaceuticals, Inc. Pyrrolopyrimidine a2b selective antagonist compounds, their synthesis and use
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
AU2003253165A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
DE102004017934A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
DE102004019492A1 (de) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
GB0412467D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
EP1847541A4 (en) 2005-02-03 2009-12-30 Takeda Pharmaceutical CONDENSED PYRIMIDINE DERIVATIVE AND USE THEREOF
JP2009528389A (ja) * 2006-03-02 2009-08-06 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ａアデノシン受容体拮抗剤
WO2007134958A1 (en) * 2006-05-18 2007-11-29 F. Hoffmann-La Roche Ag Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists
CA2670788A1 (en) * 2006-12-01 2008-06-12 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
WO2008115912A1 (en) 2007-03-21 2008-09-25 Sanofi-Aventis Regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US7947629B2 (en) * 2007-08-06 2011-05-24 Schlumberger Technology Corporation Method of acidizing sandstone formations
GB0718432D0 (en) * 2007-09-21 2007-10-31 Vernalis R&D Ltd New chemical compounds
HRP20140265T1 (hr) 2009-02-06 2014-04-25 Nippon Shinyaku Co., Ltd. Derivat aminopirazina i odgovarajuä†i lijek
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CA2804470A1 (en) 2010-07-09 2012-01-12 Bayer Intellectual Property Gmbh Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
ES2665580T3 (es) 2011-11-11 2018-04-26 Gilead Apollo, Llc Inhibidores de ACC y usos de los mismos

Also Published As

Publication number Publication date
TW201607950A (zh) 2016-03-01
US20170145029A1 (en) 2017-05-25
PH12016500608A1 (en) 2016-06-13
AU2014334040A1 (en) 2016-04-28
WO2015052065A1 (de) 2015-04-16
US9604996B2 (en) 2017-03-28
KR20160065957A (ko) 2016-06-09
IL244751A0 (en) 2016-04-21
CR20160155A (es) 2016-07-21
SG11201602397XA (en) 2016-05-30
ES2659043T3 (es) 2018-03-13
CU20160044A7 (es) 2016-09-30
NI201600047A (es) 2016-09-21
JP2016532721A (ja) 2016-10-20
AP2016009128A0 (en) 2016-04-30
CN105793267B (zh) 2018-02-06
BR112016007238A2 (pt) 2017-08-01
UY35771A (es) 2015-04-30
US20160244461A1 (en) 2016-08-25
TN2016000121A1 (en) 2017-10-06
MX2016004250A (es) 2016-07-12
EP3055313A1 (de) 2016-08-17
PE20160562A1 (es) 2016-06-05
EA201600318A1 (ru) 2016-09-30
CN105793267A (zh) 2016-07-20
CA2926223A1 (en) 2015-04-16
EP3055313B1 (de) 2017-11-22

Similar Documents

Publication Publication Date Title
ECSP14008556A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
DOP2013000007A (es) Pirimidinadas y triazinas condensadas y su uso
GT201600002A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso
DOP2015000185A (es) Pirimidinas fusionadas sustituidas con trifluorometilo y sus usos
SV2015004969A (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso
ECSP14013224A (es) Pirimidinas anilladas sustituidas y uso de las mismas
UY35693A (es) Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso
CR20160222U (es) Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
CO7131375A2 (es) Uracilos sustituidos bicíclicamente y uso de los mismos
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
MX2015009104A (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
ECSP15001882A (es) Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
UA115677C2 (uk) ПОХІДНІ ПІРОЛО[3,2-d]ПІРИМІДИНУ ДЛЯ ЛІКУВАННЯ ВІРУСНИХ ІНФЕКЦІЙ ТА ІНШИХ ЗАХВОРЮВАНЬ
CR20160155A (es) Tienouracilcarboxamidas cíclicas y usos de las mismas
SV2018005783A (es) 5,6,7,8-tetrahidro[1,2,4]triazolo[4,3-a]piridin-3(2h)-onas y 2,5,6,7-tetrahydro-3h-pyrrolo[2,1-c][1,2,4]triazol-3-ones sustituidas su uso
UY35735A (es) Trifluorometilpirimidinonas disustituidas y su uso
UY35746A (es) Derivados de fenilalanina sustituidos
CO2019002361A2 (es) 1–arilnaftiridin–3–carboxamidas 7–sustituidas y su uso
DOP2015000290A (es) Benzoxazoles sustituidos
CO6670570A2 (es) Pirimidinadas y tirazinas condensadas y su uso
CR20120445A (es) Ariltriazolonas ligadas a bisarilo y su uso
UA113887C2 (xx) 5-амінотетрагідрохінолін-2-карбонові кислоти і їх застосування